Abstract
CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have